Kimberly Page, MD
Family Medicine · Kilgore, TXNPI 1215111273
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,790 of the $5,956 with a category attached, or 97.2%. Gilead accounts for 97.2% of it on its own, with 8 other manufacturers making up the rest. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 10 payments — averaging $595.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Sanofi-aventis U.S. LLC$42
- Takeda Pharmaceuticals U.S.A., Inc.$24
- Boehringer Ingelheim$23
- Amarin Pharma, Inc.$22
- Novo Nordisk$17
- plus $39 from 3 others
What the payments were for
- Consulting fees$5,79097%
- Food & beverage$1663%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $5,790 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $17 |
| Amgen | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| GSK | 1 | $12 |
How this compares
$5,956 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 137 | $149,804 |
| OzempicSemaglutide | 124 | $127,784 |
| TrulicityDulaglutide | 52 | $68,975 |
| EliquisApixaban | 54 | $66,044 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $26,068 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $25,635 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 70 | $15,492 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $11,825 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $9,599 |
| JanuviaSitagliptin Phosphate | 15 | $7,881 |
| Gabapentin | 295 | $7,698 |
| LantusInsulin Glargine,hum.Rec.Anlog | 14 | $6,561 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 180 | $5,966 |
| Potassium Chloride | 249 | $5,103 |
| Atorvastatin Calcium | 511 | $4,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $23 | $149,804137 claims |
| Novo NordiskOzempic | $17 | $127,784124 claims |
| GSKTrelegy Ellipta, Shingrix | $12 | $41,127100 claims |
| Sanofi-aventis U.S. LLCLantus | $42 | $6,56114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Kilgore
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.